Diagnostic tests
Diagnostic TestHead-to-head comparison between:
- CADScor and Diamond-Foster score
- Rb PET and 3T CMRI
- QFR and ICA-FFR
NCT Number: NCT03481712
In a cohort of symptomatic patients referred to coronary computed tomography angiography (CCTA), the investigators aim:
1. To investigate and compare the diagnostic precision of Rubidium Positron Emission Tomography (Rb PET) and 3 Tesla Cardiac Magnetic Resonance imaging (3T CMRI) in patients where CCTA does not exclude significant coronary artery disease (CAD) using invasive coronary angiography with fractional flow reserve (ICA-FFR) as reference standard. 2. To evaluate the diagnostic precision of quantitative flow ratio (QFR) and ICA-FFR in patients where CCTA does not exclude significant CAD using Rb PET and 3T CMRI as reference standard. 3. To show superiority for the CADScor®System compared to the Diamond-Forrester score in detection of CAD with CCTA and ICA quantitative coronary angiography (ICA-QCA) as reference standard. 4. To study the diagnostic accuracy of computed tomography fractional flow reserve (CT-FFR) in patients where CCTA does not exclude significant CAD with ICA-FFR as reference standard. 5. To identify and characterize genetic risk variants´ and circulating biomarkers´ importance in developing CAD. 6. To evaluate the bone mineral density in the hip and spine and correlate this to the degree of vascular calcification.
Looking for future studies?
Notify Me30 year and older
All sexes
Observational
Aarhus University Hospital, Aarhus, Central Jutland, Denmark
CCTA has become the preferred diagnostic modality for symptomatic patients with low to intermediate risk of CAD. Of the patients examined, CCTA exclude cardiovascular disease in 70-80% with an excellent negative predictive value of more than 95%. Having a low positive predictive value, however, CCTA often overestimates the severity of CAD, especially in patients with moderate to severe coronary calcification. Following CCTA, patients are hence unnecessarily tested using golden standard ICA-FFR. These ICAs often show no obstructive coronary stenosis and are therefore not followed by revascularization. The issues outlined raises the question of whether it is possible (1) to make a more precise risk stratification and consequently better selection of patients prior to CCTA and (2) to reduce the number of patients referred for unnecessary ICAs following CCTA.
In patients with suspicion of coronary stenosis detected by CCTA, current guidelines recommend verification of myocardial ischemia. In Dan-NICAD 2, we intend to investigate the diagnostic accuracy of advanced non-invasive myocardial perfusion imaging tests; Rb PET and 3T CMRI. These examinations have shown a high diagnostic accuracy in symptomatic patients with high risk of ischemic heart disease. However, the diagnostic accuracy is not investigated in patients as follow-up after CCTA.
An alternative way to increase the diagnostic accuracy of CCTA and thus avoid unnecessary downstream testing using ICA is to utilize the ability to extract physiological information from the anatomical CCTA images. CT-FFR has in previous studies shown promising results. CT-FFR has not been head to head compared against Rb PET and 3T CMRI.
Obtained during ICA, QFR is a novel wire-free approach for fast computation of FFR with potential to increase the global use of physiological lesion assessment. QFR is superior to traditional assessment of intermediate coronary lesions (ICA-QCA diameter stenosis). However, disagreement between FFR and QFR has been identified in up to 20% of all measurements.
Acoustic detections of coronary stenosis from automatically recorded and analyzed heart sounds is a newly developed technology potentially useful for pre-test risk stratification before e.g. CCTA. One of these devices, the CADScor®System, has previously shown an area under the receiver operating characteristic curve (AUC of ROC) of 70-80% compared to conventional ICA-QCA. This indicates that the CADScor®System could potentially supplement clinical assessment of CAD and be used for risk stratification prior to CCTA.
The investigators aim to obtain blood samples for biobank purposes and record heart sounds with the CADScor®System in 2000 patients that by clinical evaluation undergo CCTA. In approximately 400 patients (20%), CCTA does not exclude significant CAD. These patients are all examined using Rb PET, 3T CMRI, and ICA with QCA. In patients with a coronary diameter stenosis of 30-90% determined during the ICA examination, FFR, coronary flow reserve (CFR) and QFR is performed.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
CADScor specific
Demography and co-existing cardiac morbidity specific
Scan specific
CCTA:
CMRI and PET:
General:
Head-to-head comparison between:
Time frame: 4 weeks after inclusion.
Head-to-head comparison using ICA-FFR as reference standard. Diagnostic accuracy is measured using specificity, sensitivity, positive and negative predictive value and likelihood ratios.
Time frame: 4 weeks after inclusion.
Head-to-head comparison using myocardial perfusion examinations as reference standard.
Diagnostic accuracy is measured using specificity, sensitivity, positive and negative predictive values, likelihood ratios and area under receiving operating curves (AUC-ROC).
Time frame: 4 weeks after inclusion.
AUC-ROC for CAD-score and Diamond-Forrester score in detection of CAD with CCTA and ICA-QCA as reference in patients ≥40 years.
Time frame: 4 weeks after inclusion.
The primary analysis will be a genome-wide association analysis, to determine candidate genes and markers underlying coronary artery disease and bone mineralization.
Time frame: 1 day after inclusion.
To study the bone mineral density in this cohort and its relation to vascular calcification.
Time frame: 4 weeks after inclusion.
Impact of coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) on myocardial perfusion imaging (MPI) diagnostic accuracy using specificity, sensitivity, positive and negative predictive values.
Time frame: 4 weeks after inclusion.
Diagnostic accuracy of quantitative CMRI analysis compared to ICA with FFR-CFR.
Time frame: 4 weeks after inclusion.
Correlation analysis between flow measurements estimated by quantitative CMRI vs. Rb PET.
Time frame: 4 weeks after inclusion.
AUC-ROCs for CAD-score and Diamond-Forrester score in detection of CAD with CCTA and ICA-QCA as reference in total population.
Time frame: 4 weeks after inclusion.
Sensitivity, specificity, negative and positive predictive value of CAD-score and Diamond-Forrester score with CCTA and ICA-QCA as reference standard.
For the CADScor®System specifically, the following criteria are applicable:
Time frame: 4 weeks after inclusion.
AUC-ROCs, sensitivity, specificity, negative and positive predictive value of CAD-score with ICA-FFR as reference standard.
Time frame: 4 weeks after inclusion.
A subgroup analysis is performed for patients with mismatch between QFR and FFR using CFR and IMR as reference standard.
Time frame: 4 weeks after inclusion.
To evaluate the diagnostic accuracy of CT-FFR using ICA-FFR as reference standard.
Time frame: 3+12 months after ICA
Evaluation of coronary revascularissation to reduce symptoms of angina pectoris 3 and 12 mdr. after ICA.
Time frame: 3+5+10 years after inclusion.
To validate the 3, 5 and 10 yr. prognostic value of a pre-test probability score including clinical, biomarker and genitic information in patients with symptoms suggestive of CAD referred for coronary CTA.
Time frame: 3+5+10 years after inclusion.
To investigate the 3, 5 and 10 yr. prognostic value of pre-specified heart sound analysis and CAD-score in patients with symptoms suggestive of CAD referred for coronary CTA.
Time frame: 3+5+10 years after inclusion.
To investigate the 3, 5 and 10 yr. prognostic value of the study's imaging techniques in patients with symptoms suggestive of CAD referred for coronary CTA.
University of Aarhus
Other
Acronym: Dan-NICAD 2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04175626
Acute Coronary Syndrome, Angina Pectoris
Fairhope, Alabama, United States
View Trial DetailsNCT05380063
Angina Pectoris, Arterial Occlusive Diseases
Beijing, China
View Trial DetailsNCT06181799
Angina Pectoris, Arterial Occlusive Diseases
Moscow, Russia
View Trial DetailsNCT03409731
Angina Pectoris, Arterial Occlusive Diseases
Nagoya, Aichi-ken, Japan
View Trial Details